Skip to main content
SpringerLink
Log in

Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Intraocular dexamethasone implant (DEXi) is an efficient treatment for diabetic macular edema (DME). However, it may be unavailable or contraindicated. Triamcinolone acetonide is another corticosteroid that has proved to be safe and effective in treating macular edema complicating various diseases including diabetes. The purpose of this study is to evaluate the outcomes of a switch from DEXi to subtenon triamcinolone acetonide (STTA) and back, in eyes with DME.

Methods

Retrospective study. DME eyes that had been treated with DEXi and switched to STTA between October 2018 and February 2019 (stock shortage of DEXi) were included. The functional and anatomical outcomes of the switch and switch-back were studied.

Results

26 eyes of 17 patients (mean age 67.1 ± 8.2 years) were considered. The mean baseline visual acuity (VA) was 0.35 ± 0.17 decimals remaining stable after DEXi, STTA and switch-back to DEXi. The mean central macular thickness (CMT) was 492.7 ± 32.8 µm initially, decreasing to 294.3 ± 133.4 µm after DEXi, 369.9 ± 182.3 µm after STTA and 297.6 ± 72.0 µm after switching back to DEXi (all p < 0.05 versus baseline). Compared to baseline, the CMT reduction was numerically better after DEXi and switching back to DEXi than after STTA (mean reduction: -200.4 µm, -167.7 µm, and -95.08 µm respectively, p = 0.13). Intraocular pressure was comparable after DEXi and STTA.

Conclusion

DEXi is the steroid of choice in DME. However, STTA can be a cost-effective alternative when DEXi is unavailable or contraindicated. This study suggests that STTA may be used in the context of a step therapy in DME.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References 

  1. Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232. https://doi.org/10.3109/08820539909069541

    Article  CAS  PubMed  Google Scholar 

  2. Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. Am J Ophthalmol 195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Munk MR, Somfai GM, de Smet MD et al (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 23:7585. https://doi.org/10.3390/ijms23147585

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vujosevic S, Toma C, Villani E et al (2020) Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 57:287–296. https://doi.org/10.1007/s00592-019-01424-4

    Article  CAS  PubMed  Google Scholar 

  5. Zhang J, Zhang J, Zhang C et al (2022) Diabetic Macular Edema: Current Understanding. Mol Mech Therapeutic Implications Cells 11:3362. https://doi.org/10.3390/cells11213362

    Article  CAS  Google Scholar 

  6. Maturi RK, Glassman AR, Liu D et al (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 136:29–38. https://doi.org/10.1001/jamaophthalmol.2017.4914

    Article  PubMed  Google Scholar 

  7. Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C et al (2019) Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15. https://doi.org/10.1186/s12886-018-1022-9

    Article  PubMed  PubMed Central  Google Scholar 

  8. Boyer DS, Yoon YH, Belfort R et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024

    Article  PubMed  Google Scholar 

  9. Patil NS, Mihalache A, Hatamnejad A et al (2023) Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: A Meta-Analysis. Ophthalmol Retina 7:289–299. https://doi.org/10.1016/j.oret.2022.10.008

    Article  PubMed  Google Scholar 

  10. Jhaveri CD, Glassman AR, Ferris FL et al (2022) Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med 387:692–703. https://doi.org/10.1056/NEJMoa2204225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Erden B, Çakır A, Aslan AC et al (2019) The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome. Ocul Immunol Inflamm 27:1235–1241. https://doi.org/10.1080/09273948.2019.1620786

    Article  CAS  PubMed  Google Scholar 

  12. Choopong P, Taetrongchit N, Boonsopon S et al (2022) Efficacy of subtenon 20-mg triamcinolone injection versus 0.1% dexamethasone eye drops for controlling inflammation after phacoemulsification: a randomized controlled trial. Sci Rep 12:16471. https://doi.org/10.1038/s41598-022-20522-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ozkurt YB, Akkaya S, Aksoy S et al (2015) Posterior Subtenon’s Capsule Triamcinolone Acetonide Injection for the Treatment of Diabetic Macular Edema. J Ocul Pharmacol Ther 31:455–460. https://doi.org/10.1089/jop.2014.0130

    Article  CAS  PubMed  Google Scholar 

  14. Jung JL, Harasawa M, Patnaik JL, Palestine AG (2022) Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis. Ophthalmol Ther 11:811–820. https://doi.org/10.1007/s40123-022-00480-4

    Article  PubMed  PubMed Central  Google Scholar 

  15. Erdogan G, Gumus G, Gunay BO, Ozkaya A (2023) Posterior sub-Tenon triamcinolone injection in the treatment of postoperative cystoid macular edema secondary to pars plana vitrectomy. Indian J Ophthalmol 71:174–179. https://doi.org/10.4103/ijo.IJO_621_22

    Article  PubMed  Google Scholar 

  16. Carbonnière C, Couret C, Blériot A et al (2017) Treatment of macular edema: Comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon’s triamcinolone injections and intravitreal dexamethasone implant. J Fr Ophtalmol 40:177–186. https://doi.org/10.1016/j.jfo.2016.11.013

    Article  PubMed  Google Scholar 

  17. Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283–295. https://doi.org/10.1016/j.ophtha.2018.08.021

    Article  PubMed  Google Scholar 

  18. Gumus G, Erdogan G, Gunay BO, Karatas Durusoy G (2022) Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. Ophthalmologica 245:439–445. https://doi.org/10.1159/000526172

    Article  CAS  PubMed  Google Scholar 

  19. He Y, Ren X-J, Hu B-J et al (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18:121. https://doi.org/10.1186/s12886-018-0779-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ehlers JP, Yeh S, Maguire MG et al (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology 129:88–99. https://doi.org/10.1016/j.ophtha.2021.07.009

    Article  PubMed  Google Scholar 

  21. Bux AV, Fortunato F, Barone A et al (2022) Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients. Eur J Ophthalmol 32:1619–1626. https://doi.org/10.1177/11206721211024804

    Article  PubMed  Google Scholar 

  22. Callanan DG, Loewenstein A, Patel SS et al (2017) A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:463–473. https://doi.org/10.1007/s00417-016-3472-1

    Article  CAS  PubMed  Google Scholar 

  23. Cellini M, Pazzaglia A, Zamparini E et al (2008) Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 8:5. https://doi.org/10.1186/1471-2415-8-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Choi YJ, Oh IK, Oh JR, Huh K (2006) Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 20:205–209. https://doi.org/10.3341/kjo.2006.20.4.205

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kurt MM, Çekiç O, Akpolat Ç et al (2017) Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema. Eye (Lond) 31:1155–1162. https://doi.org/10.1038/eye.2017.46

    Article  CAS  PubMed  Google Scholar 

  26. Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294. https://doi.org/10.1016/j.ajo.2004.09.038

    Article  CAS  PubMed  Google Scholar 

  27. Kim MW, Moon H, Yang SJ, Joe SG (2016) Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J Ophthalmol 30:25–31. https://doi.org/10.3341/kjo.2016.30.1.25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Liu B, Ma G, Hou J, Cong C (2022) Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema. J Ophthalmol 2022:6882607. https://doi.org/10.1155/2022/6882607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401–407. https://doi.org/10.1007/s10384-016-0458-9

    Article  CAS  PubMed  Google Scholar 

  30. Inoue M, Takeda K, Morita K et al (2004) Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 138:1046–1048. https://doi.org/10.1016/j.ajo.2004.05.028

    Article  CAS  PubMed  Google Scholar 

  31. Ogura Y, Shimura M, Iida T et al (2019) Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. Ophthalmologica 241:161–169. https://doi.org/10.1159/000492135

    Article  CAS  PubMed  Google Scholar 

  32. Rosenblatt A, Udaondo P, Cunha-Vaz J et al (2020) A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology 127:377–393. https://doi.org/10.1016/j.ophtha.2019.10.005

    Article  PubMed  Google Scholar 

  33. Dutra Medeiros M, Alkabes M, Nucci P (2014) Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. Eur Endocrinol 10:111–116. https://doi.org/10.17925/EE.2014.10.02.111

    Article  PubMed  PubMed Central  Google Scholar 

  34. Xia H-H, Chen J-L, Chen H-Y, Lin H-J (2020) Correlation between optical coherence tomography, multifocal electroretinogram findings and visual acuity in diabetic macular edema. Int J Ophthalmol 13:1592–1596. https://doi.org/10.18240/ijo.2020.10.13

    Article  PubMed  PubMed Central  Google Scholar 

  35. Shen Y, Liu K, Xu X (2016) Correlation Between Visual Function and Photoreceptor Integrity in Diabetic Macular Edema: Spectral-Domain Optical Coherence Tomography. Curr Eye Res 41:391–399. https://doi.org/10.3109/02713683.2015.1019003

    Article  PubMed  Google Scholar 

  36. Abd Elhamid AH (2019) Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema. J Ophthalmol 2019:8216150. https://doi.org/10.1155/2019/8216150

    Article  PubMed  PubMed Central  Google Scholar 

  37. Toda J, Fukushima H, Kato S (2009) Systemic complications of posterior subtenon injection of triamcinolone acetonide in type 2 diabetes patients. Diabetes Res Clin Pract 84:e38-40. https://doi.org/10.1016/j.diabres.2008.10.020

    Article  CAS  PubMed  Google Scholar 

  38. Kaderli B, Kivanc SA, Inan UU et al (2014) Effect of posterior subtenon injection of 40 mg of triamcinolone acetonide on glycemic control and serum cortisol and adrenocorticotropic hormone in diabetic patients. Eur Rev Med Pharmacol Sci 18:2609–2614

    CAS  PubMed  Google Scholar 

  39. Karti O, Saatci AO (2021) Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes 12:1220–1232. https://doi.org/10.4239/wjd.v12.i8.1220

    Article  PubMed  PubMed Central  Google Scholar 

  40. Mehta H, Hennings C, Gillies MC et al (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4:CD01599. https://doi.org/10.1002/14651858.CD011599.pub2

    Article  Google Scholar 

  41. Yang Y-H, Kuo H-H, Hsu W-C, Hsieh Y-T (2020) Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases. Int J Ophthalmol 13:946–951. https://doi.org/10.18240/ijo.2020.06.14

    Article  PubMed  PubMed Central  Google Scholar 

  42. Base de données publique des médicaments. https://base-donnees-publique.medicaments.gouv.fr/

  43. Tripathy K (2023) Commentary: Posterior subtenon triamcinolone - The unsung hero for managing various ocular disorders. Indian J Ophthalmol 71:181–182. https://doi.org/10.4103/ijo.IJO_1963_22

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for this work.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Sorbonne Université, Pitié-Salpêtrière University Hospital, 75013, Paris, France

    Ysé Borella, Bahram Bodaghi & Sara Touhami

  2. Ophthalmology Department, Université de Paris, APHP, Hôpital Lariboisière, 75010, Paris, France

    Samuel Bertaud, Ramin Tadayoni, Bénédicte Dupas & Sara Touhami

Authors
  1. Ysé Borella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Bertaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramin Tadayoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahram Bodaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bénédicte Dupas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sara Touhami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Touhami.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Société Française d’Ophtalmologie, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Fully informed consent was obtained from all patients.

Conflicts of interest

RT, BB, BD and ST received travel grants and consultant fees from Allergan/Abbvie, Novartis and Bayer.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ysé Borella and Samuel Bertaud participated equally to this work.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Borella, Y., Bertaud, S., Tadayoni, R. et al. Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2024). https://doi.org/10.1007/s00417-024-06492-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00417-024-06492-z

Keywords

Search

Navigation